TON March 2015 Vol 8 No 2
On the front lines of the war on cancer, nurses are often the field commanders—in charge of safely navigating patients through treacherous terrain as well as delivering medical treatment that should provide maximal health benefits and minimize adverse effects.
Results of a phase 3 study of an investigational monoclonal antibody, MABp1 (Xilonix; XBiotech), evaluated for cachexia in metastatic colorectal cancer (CRC), revealed a surprising finding: patients in the experimental arm showed a trend toward increased overall survival (an end point difficult to reach in any treatment-refractory cancer), with pharmacodynamics activity consistent with this result, investigators reported at the 2015 Gastrointestinal Cancers Symposium, held in San Francisco, California.
Bowel Dysfunction According to a recent assessment of bowel dysfunction–related needs, the hardships for colorectal cancer (CRC) survivors continue long after leaving the operating room, and survivors desire more information and strategies to help cope with unexpected changes to their bowel patterns, researchers said at the 2015 Gastrointestinal Cancers Symposium held in San Francisco, California.
A January 14, 2015, report published by the Institute of Medicine (IOM)1 walks a fine line between the competing clinical-data-sharing comfort zones of pharmaceutical companies, physician associations, patient groups, and other advocacy organizations.
At the Academy of Oncology Nurse & Patient Navigators (AONN+) Fifth Annual Conference, held in Orlando, FL, in September, one nurse was recognized by her peers for her commitment to the profession. Jessica Engel, DNP, FNP-BC, AOCNP, nurse practitioner and research assistant at the Marshfield Clinic in Stevens Point, WI, was the recipient of the 2014 Oncology Nurse Excellence (ONE) Award.
Results 1 - 10 of 10